The independent source for health policy research, polling, and news.
641 - 660 of 693 Results
The initiative would prohibit California state agencies from paying more for a prescription drug than what the Department of Veterans Affairs pays. Both sides are deploying veterans’ sympathetic and trusted image to win over voters.
The FDA, reacting to lobbying by patients and families, has approved a drug for Duchenne muscular dystrophy, a rare and lethal disease.
Drug prices rise for a variety of reasons but opportunities for the government to control them is limited.
Based on an analysis of insurance company payments, emergency room visits and lab tests were responsible for much of the overall spending.
Consumers Union says Anthem Inc. and Blue Shield of California may be exploiting furor over prescription drug prices. State regulators are looking into the issue.
A study in Health Affairs concludes that orphan drugs for rare diseases are not having a widespread or deep impact on health care spending.
Four years after a huge push to speed generics to market, the FDA has more than 4,000 generics waiting for approval.
Researchers at Harvard University examined thousands of studies to determine why drug prices have climbed and what might be done about it.
The legislation would have required drug companies to notify the state and insurers about expensive new treatments or price hikes.
Federal spending has soared for drugs that are handmade in local pharmacies, and federal investigators are raising concerns about fraud or overbilling.
Presidential candidates from both parties have proposals they say would help lower the cost of prescription drugs. But most experts say that efforts to regulate prices might not end up saving much money.
A Health Affairs study determines that Part D spending went down slightly on prescription drugs for which medical marijuana is viewed as a possible alternative.
A study in Health Affairs finds Medicare Part D beneficiaries were charged copays averaging 10.5 times more for Crestor and Nexium than generic drugs would have cost them.
Over the past few months, Massachusetts, Florida, New York, Delaware and Washington have lifted restrictions on the expensive medications, and private insurers around the country are also making the changes.
The case alleges that insured consumers were overcharged because of a contract agreement.
Proposed legislation would require drugmakers to disclose and justify price hikes. The industry has taken to Facebook and Twitter, warning that the proposal could lead to medication shortages in some regions of the state.
Amid growing concern about rising drug costs, the practices of prescription benefit management firms are drawing a new level of attention.
Staff researchers at California’s largest public buyer of health benefits say the goal of reducing drug costs for the state is appealing but might not work in the real world.
The Medicare Payment Advisory Commission outlined a package of changes to Medicare’s drug program that could save billions of dollars.
The Food and Drug Administration has introduced a simplified form that doctors will use to seek FDA approval to treat seriously ill patients with experimental drugs after other options run out.
© 2026 KFF